CD4 and neoplasm: The antitumor effect of CSF-1R inhibitor pexidartinib (PLX3397) is believed to be associated with reduced CD4+ T cells and elevated CD8+ T cells, resulting in markedly depletion of macrophages and inhibition of tumor growth [23].